Affymetrix, Inc. (NASDAQ:AFFX) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, February 2nd. Analysts expect Affymetrix to post earnings of $0.11 per share for the quarter.

Affymetrix (NASDAQ:AFFX) last announced its quarterly earnings results on Wednesday, October 28th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. The business earned $86.50 million during the quarter, compared to analysts’ expectations of $88.04 million. The business’s revenue was down .7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.08 EPS. On average, analysts expect Affymetrix to post $0.42 EPS for the current fiscal year and $0.40 EPS for the next fiscal year.

Shares of Affymetrix, Inc. (NASDAQ:AFFX) traded up 0.86% during mid-day trading on Friday, reaching $14.03. The company had a trading volume of 3,318,661 shares. Affymetrix, Inc. has a 1-year low of $8.28 and a 1-year high of $14.04. The stock has a market capitalization of $1.12 billion and a price-to-earnings ratio of 104.70. The firm has a 50-day moving average price of $11.44 and a 200-day moving average price of $9.98.

A number of research analysts recently commented on the company. Zacks Investment Research cut Affymetrix from a “buy” rating to a “hold” rating in a report on Monday, January 25th. Cantor Fitzgerald cut Affymetrix from a “buy” rating to a “hold” rating and boosted their price target for the stock from $13.00 to $14.00 in a report on Monday, January 25th. BTIG Research reissued a “hold” rating on shares of Affymetrix in a report on Thursday, October 29th. Mizuho cut Affymetrix from a “buy” rating to a “neutral” rating and set a $14.00 price target on the stock. in a report on Monday, January 11th. Finally, Cowen and Company lowered their price target on Affymetrix from $12.00 to $10.00 in a report on Tuesday, October 6th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Affymetrix currently has an average rating of “Hold” and an average target price of $12.83.

Affymetrix, Inc. is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Company maintains sales and distribution operations across the United States, Europe, Latin America and Asia. It operates in two business segments: Affymetrix Core and eBioscience. Affymetrix Core focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (NASDAQ:AFFX) and diagnostic industries. eBioscience primarily focuses on the development, manufacture, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses.

12 Month Chart for NASDAQ:AFFX

Receive News & Ratings for Affymetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.